EGFR and paronychia: Epidermal growth factor receptor (EGFR) inhibitors are essential for treating non-small cell lung cancer (NSCLC) with EGFR mutations, but they frequently cause cutaneous toxicities collectively referred to as papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors (PRIDE) syndrome.